Core Viewpoint - CASI Pharmaceuticals Inc. is transitioning to OTC Markets Group following a formal delisting from Nasdaq, which has led to a significant after-hours stock price increase of 24.48% to $0.25 [1][2]. Group 1: Delisting and Transition - The Nasdaq Hearings Panel issued a formal delisting determination due to CASI's failure to meet continued listing requirements, with trading suspension starting Thursday [2]. - CASI will not appeal the delisting decision and expects its ordinary shares to be quoted on OTC Markets Group, allowing trading to continue [2]. Group 2: Impact on Operations - CASI stated that the delisting carries "no significant impact" on its operations [3]. Group 3: Trading Metrics and Performance - CASI Pharmaceuticals has a market capitalization of $4.26 million, with a 52-week high of $3.08 and a 52-week low of $0.21 [4]. - The stock has experienced a decline of 91.13% over the past 12 months, closing the regular session down 74.06% at $0.21, currently at its annual low [4]. - The Relative Strength Index (RSI) of CASI stands at 18.40, indicating a negative price trend across all time frames according to Benzinga's Edge Stock Rankings [4][5].

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that it has received a determination letter from the Hearings Panel (the "Panel") of The Nasdaq Stock Market ("Nasdaq") dated February 23, 2026, notifying the Company that the Panel determi ...

Group 1 - Alkermes (ALKS) is currently performing well in the Medical sector, with a year-to-date gain of approximately 21.1%, significantly outperforming the average gain of 6.3% for Medical stocks [4] - The Zacks Rank for Alkermes is 1 (Strong Buy), indicating strong analyst sentiment and a positive earnings outlook, with a 9% increase in the consensus estimate for full-year earnings over the past 90 days [3] - Alkermes belongs to the Medical - Biomedical and Genetics industry, which includes 450 stocks and is currently ranked 94 in the Zacks Industry Rank, with an average gain of 20.5% year-to-date [5] Group 2 - CASI Pharmaceuticals Inc. is another Medical stock that has outperformed the sector, with a year-to-date return of 20% and a Zacks Rank of 2 (Buy) [4][5] - The Medical - Drugs industry, to which CASI Pharmaceuticals belongs, is ranked 154 and has seen a modest gain of 2.1% this year [6] - Investors in the Medical sector should monitor both Alkermes and CASI Pharmaceuticals for their strong performance trends [6]

Group 1 - The top gainers among Chinese concept stocks include: Chuangzhi Global Technology up 60.10%, Ping An Biopharmaceutical up 21.84%, Epsium Enterprise up 21.42%, Agencia Comercial Spirits up 18.34%, and CASI Pharmaceuticals up 17.65% [1] - Chuangzhi Global Technology (CGTL) closed at 2.530 with a significant increase of 118.10%, gaining 1.370 with a trading volume of 54.5447 million [1] - Ping An Biopharmaceutical (PASW) reached a price of 0.6183, reflecting a rise of 33.95%, with an increase of 0.1567 and a trading volume of 599,000 [1] Group 2 - Epsium Enterprise (EPSM) saw its stock price rise to 2.730, marking an increase of 28.17%, with a gain of 0.600 and a trading volume of 397,900 [1] - Agencia Comercial Spirits (AGCC) closed at 13.230, up 25.28%, gaining 2.670 with a trading volume of 1,000,600 [1] - CASI Pharmaceuticals (CASI) ended at 1.0650, reflecting a rise of 23.26%, with an increase of 0.2010 and a trading volume of 124,400 [1]

Core Viewpoint - CASI Pharmaceuticals has received an extension from the Nasdaq Hearings Panel to continue its listing, contingent upon regaining compliance with the Market Value of Listed Securities Rule by February 17, 2026 [1] Company Developments - The Panel's decision was influenced by recent strategic appointments, including a new Chief Executive Officer and a Non-Executive Chairman [1] - The company is focusing on the development of CID-103, an anti-CD38 monoclonal antibody aimed at treating organ transplant rejection and autoimmune diseases [1] - CASI is executing a convertible note purchase agreement and is pursuing additional financing initiatives [1] - There are plans for the divestiture of assets in China as part of the company's strategic realignment [1]

Core Viewpoint - CASI Pharmaceuticals has announced a $20 million investment through a convertible note purchase agreement to fund a Phase 1 study in China for renal allograft antibody-mediated rejection (AMR) and to develop a stable, high concentration protein solution for subcutaneous formulation [1][5]. Group 1: Investment Details - The investment will be made in tranches and is subject to multiple closings, contingent on the Purchaser's satisfaction with the Company's business results and financial status [2]. - Each convertible note will mature in 36 months, bearing an interest rate of 12% per annum, and can be converted into ordinary shares at a specified conversion price [3]. Group 2: Company Overview - CASI Pharmaceuticals is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody aimed at treating organ transplant rejection and autoimmune diseases [4][5]. - CID-103 has shown promising pre-clinical efficacy and clinical safety, and the company has received FDA IND clearance for a Phase 1 study in the U.S. [5].

Core Insights - CASI Pharmaceuticals, Inc. is developing CID-103, an anti-CD38 monoclonal antibody aimed at treating organ transplant rejection and autoimmune diseases [1] - The company presented data from a Phase 1 open-label study of CID-103 for immune thrombocytopenia (ITP) at the 67th American Society of Hematology Annual Meeting [1] Study Details - The Phase 1 study involved adult patients with ITP and utilized a dose escalation approach with intravenous infusions of CID-103 [1] - Patients were assigned to sequential dose-escalating cohorts receiving CID-103 at doses of 30 mg (n=1), 150 mg (n=1), 300 mg (n=3), 600 mg (n=3), and 900 mg (n=3) [1] - A priming dose of CID-103 was administered prior to the cohort dose, either at 30 mg or 150 mg [1]

Core Viewpoint - CASI Pharmaceuticals has appointed James Huang as Non-Executive Chairman of the Board, effective November 17, 2025, marking a significant leadership transition within the company [1] Group 1: Leadership Changes - James Huang, previously an independent board member, has been unanimously voted in as Non-Executive Chairman of CASI Pharmaceuticals [1] - Dr. Wei-Wu He will step down from his role as Executive Chairman but will continue to serve as a member of the Board of Directors [1]

Financial Performance - Revenues for Q3 2025 were $3.1 million, a 60% decrease from $7.8 million in Q3 2024, primarily due to estimated goods returns for EVOMELA[8] - Revenues for Q3 2025 decreased to $3,075,000 from $7,793,000 in Q3 2024, representing a decline of 60.5%[24] - Net loss for Q3 2025 was $10.9 million, compared to $8.4 million in Q3 2024, attributed to the decrease in revenues[11] - Net loss for Q3 2025 increased to $10,883,000 compared to a net loss of $8,395,000 in Q3 2024, an increase of 29.7%[24] - Net loss per share (basic and diluted) for Q3 2025 was $(0.67), compared to $(0.55) in Q3 2024, indicating a worsening loss per share[24] - Total comprehensive loss for the nine months ended September 2025 was $35,512,000, compared to $25,156,000 in the same period of 2024, an increase of 41.1%[24] Expenses - Cost of revenue for Q3 2025 was $2.4 million, a 35% decrease compared to $3.7 million in the same period last year[9] - General and administrative expenses for Q3 2025 were $4.9 million, a 14% decrease from $5.7 million in Q3 2024[10] - Research and development expenses for Q3 2025 were $1.4 million, stable compared to $1.5 million in the same period last year[9] - Research and development expenses for the nine months ended September 2025 were $5,073,000, slightly down from $5,251,000 in the same period of 2024, a decrease of 3.4%[24] - General and administrative expenses for the nine months ended September 2025 increased to $18,709,000 from $16,456,000 in 2024, an increase of 7.6%[24] - Selling and marketing expenses for the nine months ended September 2025 were $13,793,000, up from $13,069,000 in 2024, an increase of 5.5%[24] - Total operating expenses for Q3 2025 were $11,383,000, a reduction from $12,509,000 in Q3 2024, reflecting a decrease of 9.0%[24] Cash and Financing - As of September 30, 2025, cash and cash equivalents were $4.7 million, down from $13.5 million as of December 31, 2024[11] - The company raised approximately $5.7 million from an at-the-market facility during Q3 2025[7] Research and Development - CID-103 is in a Phase 1 dose-escalation study for immune thrombocytopenia (ITP), with dosing at the highest dose of 900 mg ongoing[6] - The company plans to present results of the ongoing Phase 1 study of CID-103 at the ASH 2025 meeting on December 7, 2025[3] Business Strategy - The company is targeting completion of the divestiture of its China business in Q2 2026[6] Shareholder Information - The weighted average number of ordinary shares outstanding increased to 16,049,321 in Q3 2025 from 15,294,393 in Q3 2024, an increase of 4.9%[24]

Core Viewpoint - CASI Pharmaceuticals, Inc. is advancing its CID-103 clinical program, targeting organ transplant rejection and autoimmune diseases, with a focus on renal allograft antibody mediated rejection (AMR) [1] Financial Results - The company reported its business and financial results for the third quarter ended September 30, 2025 [1] Clinical Development - CID-103 is positioned as a potential best-in-class anti-CD38 monoclonal antibody [1] - The clinical program for CID-103 is first being conducted in the U.S. under an already approved IND, followed by a regulatory package that has been accepted and is under review in China [1]